Login to Your Account



Safety data in hand, Oncbiomune plies prostate cancer immunotherapy

By Marie Powers
News Editor

Tuesday, February 23, 2016

Oncbiomune Pharmaceuticals Inc. is pressing ahead with a phase II trial of Proscavax, its therapeutic vaccine to treat prostate cancer, after preliminary data from a small phase I trial showed the treatment was safe and suggested initial indications of efficacy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription